ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV

Supported by the National Institutes of Health (NIH)-National Cancer Institute (NCI), under award number U54 CA242977 (US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network -ULACNet). Merck, Sharp and Dohme (MSD) provides HPV vaccine, Gardasil-9, and partial funding for vacci...

ver descrição completa

Detalhes bibliográficos
Autores: Pinto-Santini, Delia, Jalil, Emilia M., Fernandes, Giovana Teixeira, Hilaire, Genevieve, Kolevic, Lenka, Cabello, Robinson, Grinsztejn, Beatriz, Pape, William, Deschamps, Marie Marcelle, House, Margaret G., Brofsky, Emma, Sahasrabuddhe, Vikrant V., Dasgupta, Sayan, Pasalar, Siavash, Madeleine, Margaret M., Carter, Joseph, Prabhu, Priya R., Galloway, Denise, Duerr, Ann
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:Brasil
Recursos:Fundação Oswaldo Cruz (FIOCRUZ)
Repositorio:Repositório Institucional da FIOCRUZ (ARCA)
Idioma:inglés
OAI Identifier:oai:arca.fiocruz.br:icict/68939
Acesso em linha:https://arca.fiocruz.br/handle/icict/68939
Access Level:acceso abierto
Palavra-chave:HPV
HIV
Vaccination
Children
LMIC
Descrição
Resumo:Supported by the National Institutes of Health (NIH)-National Cancer Institute (NCI), under award number U54 CA242977 (US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network -ULACNet). Merck, Sharp and Dohme (MSD) provides HPV vaccine, Gardasil-9, and partial funding for vaccine shipment. NCI-DCP (Division of Cancer Prevention) has previously peer reviewed this protocol. NCI co-authors serve as collaborators (Project Scientists) as part of this Cooperative Agreement (‘U’) grant award.

Registos relacionados